US Corporate Distress Financial Stress SEC Filings — March 19, 2026

19-03-2026

Mount Logan Capital Inc. (MLCI) announced that its managed Opportunistic Credit Interval Fund (SOFIX) entered a definitive agreement to acquire over $100 million in assets from Yieldstreet Alternative Income Fund (YS AIF), nearly doubling SOFIX's size and expected to boost MLCI's annual fee-related earnings (FRE) by at least $2.8 million, or more than 30% of trailing twelve-month FRE as of December 31, 2025. The transaction, including a Transition Services Agreement (TSA) with Willow Wealth, is projected to be immediately accretive to FRE upon closing in late Q2 or Q3 2026, subject to regulatory and YS AIF shareholder approvals. MLCI had over $2.1 billion in assets under management as of December 31, 2025.

• ·YS AIF suspended share offerings effective immediately, but automatic dividend reinvestment plan continues.
• ·Transaction unanimously approved by SOFIX Board of Trustees and YS AIF Board of Directors.
• ·Intended as tax-free reorganization for YS AIF shareholders; no SOFIX shareholder vote required.
• ·TSA stock subject to lock-up provisions.

19-03-2026

AMERICAN VANGUARD CORPORATION (as Holdings) and AMVAC CHEMICAL CORPORATION (as Borrower) entered into a Credit and Guaranty Agreement dated March 13, 2026, with Wilmington Trust, National Association as Administrative Agent and certain lenders, establishing a senior secured term loan facility with an aggregate principal amount of $225 million. The facility provides financing subject to covenants, representations, and events of default, with interest rates starting at Term SOFR plus 8.25% or Base Rate plus 7.25%, eligible to step down based on improvements in the Consolidated Total Leverage Ratio below thresholds like 4.00:1.00. No prior period financial performance data or comparisons are disclosed in the filing.

• ·Compliance Certificate due two business days after quarterly financials for fiscal quarter ending June 30, 2026, to potentially adjust Applicable Margin.
• ·ABL Facility permitted if approved by Required Lenders, secured junior to term loan on non-ABL Priority Collateral.

19-03-2026

SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced on March 17, 2026, a proposed underwritten public offering of common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase up to an additional 15% of the securities. Net proceeds, along with existing cash, will primarily fund the development of clinical-stage candidate SAB-142 through ongoing and planned trials, manufacturing, regulatory activities, and general corporate purposes. The offering is subject to market conditions with no assurance of completion or final terms.

• ·Shelf registration statement on Form S-3 (No. 333-292482) filed December 29, 2025, declared effective January 7, 2026.
• ·Joint book-running managers: Jefferies, UBS Investment Bank, Citigroup, Barclays; lead manager: Chardan.

19-03-2026

On March 17, 2026, The Cannabist Company Holdings Inc. secured a further extension of a forbearance agreement from an ad hoc group of noteholders for its 9.25% Senior Secured Notes due December 31, 2028, and 9.00% Senior Secured Convertible Notes due December 31, 2028, postponing any exercise of remedies until March 25, 2026. This development signals ongoing financial stress and potential covenant issues under the amended indenture. No financial metrics or performance data were disclosed.

• ·Registrant is an emerging growth company.
• ·Principal executive offices: 321 Billerica Road, Chelmsford, Massachusetts 01824.
• ·Telephone: (978) 910-1486.
• ·No securities registered pursuant to Section 12(b) of the Act.

19-03-2026

DevvStream Corp. reduced outstanding debt by approximately $5.9 million net of a new $700,000 0% interest loan from Helena Partners, through Focus Impact Partners converting $5.5 million of 5.3% notes and fees into equity at a 12.9% premium, and prepaying $1.1 million to Helena from released $1.2 million collateral. These moves strengthen the balance sheet and signal partner confidence. However, forward-looking risks highlight potential insufficient liquidity from the new loan, Nasdaq delisting threats, and operational constraints from existing debt.

• ·FIP 5.3% convertible notes due November 2026
• ·Helena convertible note dated July 17, 2025
• ·Helena interest waiver through May 2026
• ·New Helena loan due March 2027
• ·Announcement date: March 13, 2026
• ·Filing date: March 19, 2026

19-03-2026

Horizon Technology Finance Corporation (NASDAQ: HRZN) announced the formation of a new joint venture with CR Financial Holdings, Inc. (CRFH), with initial capital commitments totaling $100 million to provide growth capital financing solutions, primarily secured loans in the $5-25 million range, to small- and micro-cap public companies in the U.S. The joint venture features equal governance representation from both parties and expects support from Monroe Capital, which manages $24 billion in assets as of January 1, 2026. No negative performance metrics were reported in this announcement.

• ·Joint venture governance: four-person board and investment committee with equal representation from Horizon and CRFH
• ·Announcement date: March 19, 2026
• ·Monroe Capital supports larger investments

19-03-2026

Ares Aspen Member LLC, as Borrower, and Ares Aspen Holdings LLC, as Pledgor, entered into a First Amendment to the Credit Agreement and Pledge and Security Agreement dated March 13, 2026, with MUFG Bank, Ltd. as Administrative Agent, BNP Paribas as Collateral Agent, and certain Lenders, to provide Incremental Facilities including First Amendment Term Loan Commitments, First Amendment DDTL Commitments, and increased DSR LC commitments in connection with the ACI Sierra Acquisition and Sierra Acquisition. The amendment is subject to conditions precedent such as no Material Adverse Effect, solvency certification, updated financial model satisfying Debt Sizing Parameters, and payment of a 0.125% Consent Fee on outstanding Term Loans and DSR LC Loan Commitments. No quantitative performance metrics or declines are disclosed in the filing.

• ·Original Credit Agreement and Pledge and Security Agreement dated March 14, 2025.
• ·Amendment effective upon satisfaction of conditions including resolutions, good standing certificates, financial statements from Sierra Purchase and Sale Agreement, solvency certificate, legal opinion from Kirkland & Ellis LLP, perfected liens on Sierra Target equity, no Material Adverse Effect since Closing Date or Latest Balance Sheet Date, and DSR Account funded to Minimum Debt Service Reserve Amount.
• ·Updated Base Case Lender Financial Model required to show Term Loans satisfy Debt Sizing Parameters post-Sierra Acquisition.

19-03-2026

SPAR Group, Inc.'s wholly-owned subsidiary, SPAR Marketing Force, Inc., entered into a $4M unsecured loan with PC Group, Inc., effective March 13, 2026, with an initial $3M drawdown on March 16, 2026, and the remaining $1M available in July 2026. The loan bears 8% annual interest with monthly interest-only payments and full repayment due in 36 months on March 16, 2029, accompanied by the issuance of 1M shares of SGRP common stock valued at $800K to reduce principal (subject to adjustment if shares issued below $0.80). While providing liquidity, the arrangement introduces debt servicing costs, equity dilution, and SGRP's unconditional guarantee.

• ·Loan evidenced by Senior Unsecured Promissory Note effective March 13, 2026
• ·SGRP joined as unconditional guarantor
• ·Share issuance to occur within 30 days after Note execution, subject to securities laws
• ·Principal reduction from shares adjustable if SGRP issues shares below $0.80 per share during 36-month term

19-03-2026

Evofem Biosciences, Inc. (Buyer) and Windtree Therapeutics, Inc. (Supplier) mutually terminated their License and Supply Agreement (dated March 20, 2025, as amended) effective March 13, 2026, because Windtree failed to establish manufacturing capabilities for Evofem's Phexxi product. No termination fees are due to either party, with each bearing their own costs, but Windtree must immediately cease using Evofem's IP and return all confidential information and assets. This termination eliminates the supply arrangement without further obligations, potentially disrupting Evofem's Phexxi production.

• ·Agreement governed by Delaware law with exclusive jurisdiction in Delaware courts.
• ·Certain sections of the original License and Supply Agreement (per Section 11.6) survive termination.

19-03-2026

Cheniere Energy, Inc. entered into a Registration Rights Agreement dated March 19, 2026, governing $1B of 5.200% Senior Notes due 2036 and $750M of 6.000% Senior Notes due 2056 issued pursuant to indentures with The Bank of New York Mellon as trustee and sold to initial purchasers led by Goldman Sachs & Co. LLC under a March 5, 2026 Purchase Agreement. The agreement requires the company to file an Exchange Offer Registration Statement within 360 days of the Issue Date to enable holders to exchange unregistered Initial Securities for registered Exchange Securities, or pursue a Shelf Registration if the exchange offer cannot be completed or certain holders remain ineligible. No comparative financial performance data is provided in the filing.

• ·Purchase Agreement dated March 5, 2026.
• ·Base Indenture, First Supplemental Indenture, and Second Supplemental Indenture all dated March 19, 2026.
• ·Exchange Offer Registration Statement to become effective within 360 days of Issue Date; offer to remain open not less than 20 Business Days.
• ·Shelf Registration Statement to remain effective for up to one year from Issue Date if triggered.

19-03-2026

Scorpius Holdings, Inc. entered into three non-convertible promissory notes with an institutional investor, with principal amounts of $30,426.95 (Feb 12, 2026), $190,907.77 (Feb 26, 2026), and $27,109.10 (Mar 11, 2026), totaling approximately $248,444. Each note carries 5% annual interest, a 15% premium on principal at maturity/redemption/prepayment, and matures in August-September 2026 or earlier upon corporate events or default. The notes impose short-term debt obligations with redemption rights using up to 100% of future financing proceeds and default triggers for unpaid indebtedness over $150,000.

• ·Notes issued in reliance on Section 4(a)(2) of the Securities Act and/or Regulation D exemption.
• ·Holder has right to require redemption of outstanding balance using up to 100% of gross proceeds from any subsequent Financing.

19-03-2026

Revelation Biosciences, Inc. held a Special Meeting of Stockholders on March 18, 2026, where shareholders overwhelmingly approved Proposal 1 to authorize the issuance of common stock pursuant to Class J Common Stock Warrants (issued January 26, 2026) to exceed Nasdaq's 20% Exchange Cap, with 4,033,345 votes for, 104,162 against, and 34,228 abstentions out of 4,171,735 shares present (quorum met from 10,492,469 outstanding shares). Proposal 2 for discretionary adjournment also passed strongly (4,044,322 for, 92,422 against). Following approval, the warrants' expiration date extends to March 18, 2031.

• ·Definitive proxy statement filed with SEC on February 17, 2026
• ·Warrant inducement letter dated January 23, 2026
• ·No broker non-votes on either proposal
• ·Common stock par value $0.001 per share

19-03-2026

Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced a proposed public offering of shares of common stock (or equivalents) and warrants, with net proceeds intended to fund R&D activities including the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, alongside working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent. However, the offering is subject to market and other conditions, with no assurance as to completion, timing, size, or terms.

• ·Shelf registration statement on Form S-3 (File No. 333-276848) filed February 2, 2024, effective February 13, 2024.
• ·References risks in Form 10-K for year ended December 31, 2024, and 10-Qs for quarters ended March 31, 2025, June 30, 2025, and September 30, 2025.

19-03-2026

Vince Holding Corp. (through V OPCO, LLC) entered into a Second Amendment to its Credit Agreement on March 18, 2026, with Bank of America, N.A. as agent, amending definitions related to Eligible Trade Receivables. Key changes include adjusting the general Concentration Limit to 20% and specific limits to 50% for Nordstrom (and affiliates), 35% for TJX and Macy’s (and affiliates), and 30% for Saks Global (and affiliates), along with modifications for account debtors in bankruptcy proceedings. The amendment confirms no Default or Event of Default exists and maintains all existing obligations.

• ·Original Credit Agreement dated June 23, 2023.
• ·First Amendment to Credit Agreement dated January 22, 2025.
• ·Amendment also updates clause (j) of Eligible Trade Receivables to allow Agent discretion for accounts from debtors in Chapter 11 operating as debtor-in-possession with super priority lien/administrative claim.

19-03-2026

Corvex, Inc. announced the closing of an all-stock merger with Movano Inc. on March 19, 2026, pursuant to which Movano will be renamed Corvex, Inc. effective March 23, 2026, and continue trading on Nasdaq under 'MOVE'. Prior to the merger, Corvex and Movano raised $40.2 million to expand its AI infrastructure platform. The merger includes issuance of preferred stock convertible into common stock (Series B up to 19.9% ownership), a stock dividend of 0.358 shares per common share (record date March 30, 2026), and upcoming stockholder meeting by May 31, 2026, for approvals including conversions and leadership changes.

• ·Issued 240.562 shares of Series B Convertible Preferred Stock (auto-converts to 240,562,000 common shares on March 31, 2026).
• ·Issued 23,551.5195 shares of Series C Non-Voting Convertible Preferred Stock (conversion subject to stockholder approval; each converts to 1,000 common shares).
• ·Issued 30,227.0524 shares of Series D Non-Voting Convertible Preferred Stock (conversion subject to approval; each converts to 1,000 common shares; 4.99% ownership limit).
• ·2026 Stockholders’ Meeting no later than May 31, 2026, to vote on conversions, option exercises, director elections, auditor ratification, and equity incentive plans.
• ·Merger qualifies as tax-free reorganization under IRC Section 368(a).

19-03-2026

Aclarion, Inc. announced that its Board unanimously adopted a limited duration stockholder rights plan, effective immediately and expiring in one year on March 18, 2027, to protect shareholder value by deterring unapproved acquisitions of 10% or more of common stock without a control premium. Rights will distribute as a dividend on March 30, 2026, for each share of common stock and Rights-Eligible Warrants, becoming exercisable upon triggering events to allow holders (excluding the acquirer) to purchase preferred stock equivalent to twice the $14.00 exercise price in common stock value. The plan applies equally to all stockholders, grandfathering existing >10% owners from triggering if they do not increase holdings, and was not adopted in response to any specific takeover threat.

• ·Rights attach to each share of Common Stock (par value $0.00001) and Rights-Eligible Warrants as of Record Date March 30, 2026
• ·Board may redeem rights at $0.001 per right or exchange for one share of Common Stock per right
• ·No dead-hand, slow-hand, or similar features limiting future Board actions
• ·Aclarion leverages MRS, biomarkers, and AI for chronic low back pain via Nociscan SaaS platform

19-03-2026

Humacyte, Inc. announced the pricing of a $20M registered direct offering of 25M shares of common stock, led by a new life science investor and a long-only mutual fund, with gross proceeds expected before deducting expenses. Net proceeds will fund Symvess commercialization in vascular trauma, a BLA supplement filing for hemodialysis including upcoming Phase 3 readout, pipeline development, and general corporate purposes. The offering is expected to close on or about March 20, 2026.

• ·Shelf registration statement (Form S-3 No. 333-290231) filed September 12, 2025, declared effective September 22, 2025
• ·United States commercial launch of Symvess commenced in Q1 2025
• ·Titan Partners acting as sole placement agent

19-03-2026

Origin Materials, Inc. amended its Amended and Restated Certificate of Incorporation to authorize 1,000,000,000 shares of Common Stock (par value $0.0001) and 10,000,000 shares of Preferred Stock (par value $0.0001), effective March 19, 2026. The amendment also implements a 1-for-30 reverse stock split on Common Stock, with no fractional shares issued and holders of fractional shares receiving one full share. The change was approved by stockholders per Delaware General Corporation Law and signed by CEO John Bissell.

• ·Original Certificate of Incorporation filed June 24, 2021, effective 5:15 p.m.
• ·Amended and Restated Certificate filed June 24, 2021, effective 12:01 a.m. June 25, 2021.

19-03-2026

Verde Renewables Inc., a wholly owned subsidiary of Verde Resources, Inc., entered into a Supply Agreement with Biochar Solutions LLC on March 14, 2026, designating BSL as the exclusive U.S. supplier of up to 38,500 tons of engineered biochar annually for asphalt and road construction applications, with at least 50% qualifying for carbon removal credits and revenue sharing on credits. The parties plan to jointly file and own a U.S. patent for their engineered biochar blend and intend to negotiate a subsequent 5-year agreement after the initial 18-month term. No financial performance metrics or declines were reported.

• ·BSL to forward leads for biochar-based or low emissions asphalt exclusively to Verde
• ·Agreement term: 18 months initial period, then month-to-month if no Subsequent Agreement
• ·Termination: 60 days prior written notice for any reason or 15 days to cure material breach
• ·Subsequent Agreement: 5-year term, renewable for additional 5 years with 120 days notice

19-03-2026

AVAX One Technologies Ltd. received a Nasdaq notice on March 13, 2026, stating non-compliance with Listing Rule 5550(a)(2) due to its common stock's closing bid price being below $1.00 for 30 consecutive business days. The company has requested a hearing before a Nasdaq Hearings Panel, automatically staying any delisting, with potential for up to 180 days extension to regain compliance. No assurances exist that the Panel will grant relief or that listing will be maintained.

• ·Nasdaq Listing Rule 5810(c)(3)(A)(iv) applies to hearing process
• ·Commission File Number: 001-40578
• ·Registrant is an emerging growth company
• ·Common Shares traded as AVX on The Nasdaq Capital Market

19-03-2026

SmartKem, Inc., a Delaware corporation with UK offices, entered into a Securities Purchase Agreement dated as of 2026 for the issuance and sale of senior secured notes with an aggregate original principal amount of $3.75M to accredited investors under Regulation D exemptions. Buyers will pay $700 for each $1,000 of principal, providing the company with immediate cash proceeds at a discount while the notes rank senior to all other indebtedness and are secured by first-priority liens on all existing and future assets of the company and its subsidiaries, including pledges of subsidiary stock. No financial performance comparisons or declines are disclosed in the agreement.

• ·Closing to occur at 10:00 a.m. New York time on the first Business Day conditions are met at offices of Meister Seelig & Fein PLLC, 125 Park Avenue, 7th Floor, New York, NY 10017
• ·Notes issued in reliance on Section 4(a)(2) of the 1933 Act and Rule 506(b) of Regulation D
• ·Purchase price paid by wire transfer per Flow of Funds Letter; company delivers executed Notes registered to Buyers
• ·Subsidiaries provide guaranties; security via Security Agreement, Perfection Certificate, and other Security Documents

19-03-2026

The AES Corporation entered into amendments to three credit agreements on March 13 and 16, 2026: Amendment No. 2 to the Citi Credit Agreement (dated September 24, 2021), First Amendment to the SMBC Credit Agreement (dated December 6, 2024), and Amendment No. 1 to the Barclays Letter of Credit Agreement (dated December 8, 2025). These amendments modify change of control provisions to permit ownership by Global Infrastructure Management, LLC, EQT Fund Management S.à r.l., Qatar Investment Authority, and affiliates, following the March 2, 2026 announcement of a merger agreement with Horizon Parent, L.P. and Horizon Merger Sub, Inc. No financial terms or impacts from the amendments are disclosed in the filing.

• ·Citi Second Amendment executed March 13, 2026 (Exhibit 10.1)
• ·SMBC First Amendment executed March 16, 2026 (Exhibit 10.2)
• ·Barclays First Amendment executed March 16, 2026 (Exhibit 10.3)
• ·Filing signed March 19, 2026

19-03-2026

Wolfspeed announced private placements for $379M aggregate principal of 3.5% Convertible 1.5 Lien Senior Secured Notes due 2031 and $96.9M in common stock (3,250,030 shares) and pre-funded warrants (for 2M shares), expecting total gross proceeds of $475.9M. Proceeds will redeem $475.9M of outstanding higher-cost Senior Notes, reducing annual interest expense and total debt to strengthen the balance sheet. This supports diversification into emerging markets like AI data centers, industrial and energy, and aerospace/defense.

• ·Subscription agreements entered March 19, 2026; settlement expected March 26, 2026
• ·Notes mature March 15, 2031; interest payable semi-annually starting September 15, 2026
• ·Initial conversion rate: 49.6623 shares per $1,000 principal (approx. $20.14 conversion price)
• ·Closing price March 18, 2026: $16.78 per share
• ·Notes secured by substantially all assets of Wolfspeed and Guarantor

19-03-2026

Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) on March 19, 2026, enabling the company to offer and sell up to $100M in common stock via at-the-market offerings pursuant to an effective S-3 Registration Statement. Proceeds are intended for general corporate purposes, including research and development, clinical trials, capital expenditures, and working capital. TD Cowen will receive compensation of up to 3.0% of gross proceeds, with customary termination rights for both parties.

• ·Sales Agreement filed as Exhibit 1.1; Legal opinion of Cooley LLP as Exhibit 5.1
• ·Registration Statement on Form S-3 (File No. 333-276847) filed February 2, 2024, effective February 13, 2024
• ·Prospectus supplement to be filed with SEC on March 19, 2026

19-03-2026

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a definitive agreement to acquire the AZSTARYS ADHD treatment business from Corium Therapeutics for $650M in cash plus up to $135M in commercial and regulatory milestones, funded by cash on hand and a $300M delayed draw term loan. The acquisition, expected to close in Q2 2026, is projected to generate over $50M in pro forma net revenue for AZSTARYS in H2 2026, deliver >$50M in annual run-rate synergies within 12 months, and be immediately accretive to adjusted EBITDA while extending patent protection to 2037. AZSTARYS generated over 760,000 prescriptions in 2025, complementing Collegium's existing JORNAY PM® ADHD portfolio.

• ·Expected net leverage approximately 2x post-close based on 2026 combined adjusted EBITDA
• ·Term loan interest rate: SOFR plus 3.25% upon closing
• ·AZSTARYS supported by six Orange Book-listed patents, most expiring December 2037
• ·Conference call held March 19, 2026 at 9:00 a.m. ET

19-03-2026

Twin Vee PowerCats Co. (NASDAQ: VEEE) announced the pricing of a best-efforts at-the-market offering of 4,473,000 shares of common stock at $0.38 per share under Nasdaq rules, expecting gross proceeds of approximately $1.7 million before fees and expenses. The offering is anticipated to close on March 17, 2026, subject to customary conditions, with net proceeds intended for working capital and general corporate purposes. ThinkEquity is serving as the sole placement agent.

• ·Shelf registration statement on Form S-3 (File No. 333-293911) filed February 27, 2026, and declared effective March 5, 2026.
• ·Company located in Fort Pierce, Florida, with 30 years of building and selling boats.

19-03-2026

HyOrc Corporation entered into a Securities Purchase Agreement with GS Capital Partners, LLC on March 13, 2026, issuing a Convertible Promissory Note with $150,000 principal, $11,000 original issue discount, netting $139,000 before ~$4,000 expenses. The note matures September 13, 2026, and is convertible into common stock at 77% of the lowest trading price over the prior 10 trading days, with 250,000 returnable shares issued as collateral and up to 5,000,000 shares reserved for conversion. The transaction relied on exemptions under Section 4(a)(2) and Regulation D for unregistered securities.

• ·Note issued in reliance on Section 4(a)(2) of Securities Act and/or Regulation D.
• ·Irrevocable Transfer Agent Instruction Letter executed with Investor and transfer agent.
• ·Exhibits include SPA (10.1), Note (10.2), Transfer Agent Instruction (10.3), and Reserve Letter (10.4).

19-03-2026

Alliant Energy Corporation entered into a Distribution Agreement on March 19, 2026, with multiple agents including Barclays Capital Inc., BofA Securities, Inc., and others, allowing sales of common stock shares with an aggregate offering price of up to $1B at market prices via ordinary brokers' transactions or block trades. The agreement also permits forward confirmations with forward purchasers for hedging, with net proceeds intended for general corporate purposes such as debt repayment, refinancing, working capital, and investments. No proceeds are received initially from borrowed shares sold by forward sellers.

• ·Sales executed on Nasdaq Global Select Market; shares issued under Registration Statement on Form S-3 (No. 333-276062).
• ·Agents' affiliates are lenders under the Company's revolving credit facility.
• ·Prospectus supplement filed March 19, 2026.

19-03-2026

SmartStop Self Storage REIT, Inc. and SmartStop OP, L.P. entered into a distribution agreement on March 19, 2026, with multiple sales agents including J.P. Morgan Securities, LLC and others, to issue and sell shares of common stock with an aggregate offering price of up to $300 million via an at-the-market offering program. The agreement also includes forward sale agreements with forward purchasers such as JPMorgan Chase Bank, National Association. Net proceeds, if any, will be used for general corporate purposes including acquisitions, development, and debt reduction; sales agents will receive commissions not exceeding 2.0% of gross sales price.

• ·Shares traded on New York Stock Exchange under symbol SMA
• ·Pursuant to automatic shelf registration statement on Form S-3 (File No. 333-292583) filed January 5, 2026
• ·Prospectus supplement filed March 19, 2026
• ·Legal opinion by Nelson Mullins Riley & Scarborough LLP (Exhibit 5.1)

19-03-2026

Skye Bioscience, Inc. received a Nasdaq deficiency notice on March 17, 2026, stating that its common stock (SKYE) closing bid price was below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5450(a)(1). The company has 180 calendar days until September 14, 2026, to regain compliance, potentially through a reverse stock split, with trading continuing uninterrupted for now. However, there is no assurance of compliance, and failure could lead to transfer or further review.

• ·Nasdaq deficiency letter issued by Nasdaq Listing Qualifications Department
• ·Compliance possible if bid price closes at $1.00 or more for 10 consecutive business days
• ·Reverse stock split, if implemented, must be completed no later than 10 business days before September 14, 2026
• ·Potential second 180-day compliance period if qualifying for Nasdaq Capital Market standards (except bid price)

19-03-2026

Signing Day Sports closed its business combination with BlockchAIn Digital Infrastructure on March 16, 2026, pursuant to the May 27, 2025 agreement, resulting in Signing Day Sports and One Blockchain becoming wholly-owned subsidiaries of BlockchAIn and a change in control. Key executives and directors including CEO Daniel Nelson, CFO Damon Rich, and others resigned effective Closing, with Jerry Tang appointed as new CEO and director, and Jolienne Halisky as CFO; compensatory grants of restricted shares were issued prior to resignations. The company terminated its July 21, 2025 Purchase Agreement with Helena Global effective March 20, 2026, and issued 3,172,704 unregistered shares to Boustead Securities.

• ·Termination notice for Purchase Agreement given March 13, 2026, effective March 20, 2026.
• ·NYSE American authorized Additional Termination Shares issuance subject to stockholder approval, obtained March 13, 2026.
• ·Exchange Ratio determined as last reported sale price of Signing Day Sports common stock prior to Closing divided by 7.5, rounded up for fractions.
• ·Shares issued in reliance on Section 4(a)(2) and/or Rule 506(b) of Regulation D.
• ·Resignations not due to any disagreement with Company operations, policies, or practices.

19-03-2026

Datavault AI Inc. (DVLT) signed a definitive agreement on March 19, 2026, to acquire NYIAX Inc., integrating NYIAX's blockchain-powered trading platform and patents with Datavault AI's AI-driven data monetization technologies to launch specialized exchanges like Information Data Exchange®, International Elements Exchange, American Political Exchange, Sports-Centered NIL Exchange, and NYIAX Advertising Exchange. The deal builds on prior collaborations including a March 2025 partnership, October 2025 letter of intent, and January 28, 2026 Sports Illustrated agreement. While positioned as transformative for digital asset trading, it remains subject to closing conditions and risks such as regulatory changes, integration challenges, and potential failure to close.

• ·U.S. Patent Nos. 10,607,291 and 11,410,236 titled “Systems and Methods for Electronic Continuous Trading of Variant Inventories.”
• ·Prior multi-year commercial and IP licensing agreements dating back to March 2025.
• ·October 2025 letter of intent between Datavault AI and NYIAX.
• ·Datavault AI's Annual Report on Form 10-K for year ended December 31, 2025.

19-03-2026

Forward Industries announced the repurchase of 6,164,324 common shares for $27.4M from an institutional investor, reducing common shares outstanding from 83,142,133 to 76,977,809 and fully diluted shares from 111,591,332 (as of Dec 31, 2025) to 105,894,207, boosting SOL-per-share from 0.0624 to 0.0662 (29% annualized increase). The transaction is financed by a $40M loan from Galaxy Digital LLC at 3.4% APR with 4.9-month maturity, secured by fwdSOL while retaining staking rewards. The company expects SG&A expenses (excluding stock-based comp and design segment) to decline 45% from $6.5M in fiscal Q1 to $3.6M in fiscal Q3 via cost optimizations.

• ·Loan secured by fwdSOL held in treasury, with Company retaining staking rewards on underlying SOL.
• ·Private placement transaction in September 2025 launched digital asset treasury strategy.

19-03-2026

Rivian Automotive, Inc. (RIVN) and Uber Technologies, Inc. (UBER) announced a partnership to deploy 10,000 fully autonomous R2 robotaxis initially, with an option for up to 40,000 more (total 50,000), starting in San Francisco and Miami in 2028 and scaling to 25 cities by 2031. Uber committed to invest up to $1.25B through 2031 subject to autonomy milestones, including an initial $300M post-regulatory approval. The partnership leverages Rivian's third-generation autonomy platform, announced in December 2025, featuring advanced sensors and 1600 TOPS compute.

• ·Rivian third-generation autonomy platform announced December 2025, launching in R2 late 2026.
• ·Deployments exclusively through Uber platform.
• ·Option to negotiate additional 40,000 R2 vehicles beginning 2030.

19-03-2026

Lithium Americas Corp. entered into an Equity Distribution Agreement with TD Securities (USA) LLC on March 19, 2026, for an at-the-market (ATM) offering program allowing sales of up to $250M in common shares from time to time. The agent will receive a commission of up to 3.0% of gross proceeds, with net proceeds intended for general corporate purposes such as overhead expenses, capital expenditures, debt repayment, and working capital. No shares are obligated to be sold under the agreement.

• ·Agreement pursuant to shelf registration statement on Form S-3 (File No. 333-287327), filed May 15, 2025 and effective May 23, 2025.
• ·Prospectus Supplement covering the $250M offering filed with SEC on March 19, 2026.
• ·Legal opinion on validity of Common Shares issuance provided by Cassels Brock & Blackwell LLP (Exhibit 5.1).

19-03-2026

Getty Images Holdings, Inc. received NYSE notice on March 17, 2026, for non-compliance with continued listing standard Section 802.01C due to average Class A common stock closing price below $1.00 over 30 consecutive trading days. The company has a six-month cure period to regain compliance by achieving a $1.00 closing price and 30-day average, with no immediate delisting or trading suspension, and intends to notify NYSE of cure plans within 10 business days. Trading continues subject to other listing standards, with no impact on operations.

• ·Compliance can be regained on the last trading day of any calendar month during the six-month period if closing share price >= $1.00 and 30-day average >= $1.00.
• ·Press release furnished as Exhibit 99.1, not deemed 'filed' under Exchange Act.
• ·Risk factors referenced from 10-K for year ended December 31, 2025.

19-03-2026

BiomX Inc. issued a CEO letter announcing a strategic and financial reset, including leadership changes, amendment of December 2025 warrants to a one-year exercise period at $1.00 per share to reduce overhang, and cost reductions such as closing the Maryland facility. While these steps aim to simplify the capital structure and position the company for growth in defense-related sectors, they reflect a challenging transition period with ongoing uncertainties. The company is engaging investors and advisors for future opportunities but highlights risks to cash resources.

• ·Warrants originally had a five-year term, now amended to one-year exercise period.
• ·Recent investment completed in December 2025.
• ·Annual Report on Form 10-K filed February 19, 2026.

19-03-2026

Subsidiaries of CBL & Associates Properties Inc., including entities such as Cherryvale Mall, LLC, Kirkwood Mall Acquisition LLC, and others, entered into a Loan Agreement dated March 13, 2026, with Goldman Sachs Bank USA to finance multiple retail properties including Kirkwood Mall, Post Oak Mall, and Westmoreland Parcel. The agreement establishes cash management accounts, defeasance options, and various affirmative and negative covenants related to property maintenance, leasing, and financial reporting. No specific loan amounts or financial performance metrics are disclosed in the provided filing content.

• ·Filing Date: March 19, 2026
• ·Loan Agreement Effective Date: March 13, 2026
• ·SEC Items Reported: 1.01, 2.03, 8.01, 9.01
• ·Approved Property Manager: CBL & Associates Management, Inc.
• ·Schedules include Properties and Square Footage (Schedule A), Allocated Loan Amounts (Schedule G), and others

19-03-2026

American Shared Hospital Services entered into Amendment Two to its Proton Beam Radiation Therapy Lease Agreement with Orlando Health, Inc., extending the lease term for an additional seven years from April 6, 2026, through April 5, 2033. The amendment establishes lease payments based on a technical component collection percentage that decreases during certain 12-month periods of the extended term, and grants Orlando Health an option to purchase the leased proton beam radiation therapy system at the end of the term. It also details the Company's obligation to remove the equipment at its expense if the purchase option is not exercised, along with related maintenance and insurance terms.

• ·Original Lease dated October 18, 2006, amended August 12, 2012
• ·Amendment dated/effective March 13, 2026

19-03-2026

Camden Property Trust entered into the Fifth Amended and Restated Credit Agreement on March 17, 2026, amending and restating in its entirety the prior Fourth Amended and Restated Credit Agreement dated August 31, 2022, without constituting a novation of existing obligations. Bank of America, N.A. acts as Administrative Agent and L/C Issuer, with JPMorgan Chase Bank, N.A., PNC Bank, National Association, Regions Bank, Truist Bank, and U.S. Bank National Association as Syndication Agents, and others as Documentation Agents. The agreement outlines commitments for loans, borrowings, letters of credit, and applicable rates tiered by debt ratings from S&P/Moody's, with no specific aggregate commitment amount disclosed in the filing excerpt.

• ·Debt Rating determines Applicable Rate across 7 pricing levels, with higher ratings yielding lower fees and spreads.
• ·CUSIP Nos: Published Deal 13313BAQ3, Published 13313BAR1.
• ·Schedules include Commitments and Applicable Percentages (Schedule 2.01), but details not provided in excerpt.

19-03-2026

RGC Resources, Inc. (Guarantor) and its subsidiary Roanoke Gas Company (Borrower) entered into the First Amendment to Amended and Restated Promissory Note and Third Amendment to Amended and Restated Loan Agreement with Pinnacle Bank on March 17, 2026, extending the revolving note maturity from March 31, 2027 to March 31, 2028. The revolving loan commitment remains at $30M until March 31, 2027, but temporarily reduces to $20M from April 1, 2027 to September 30, 2027 before returning to $30M; an uncommitted accordion feature allows for a potential $5M increase at the lender's discretion. No events of default were reported, and all parties ratified the existing loan documents.

• ·Previous amendments: March 24, 2023 (original Loan Agreement), March 31, 2024 (first amendment), March 31, 2025 (second amendment to Loan Agreement)